NVO’s price collapsed in 2016 on fears of insulin pricing pressure. From a high of $57.31 in June 2016 it dropped to a low of $31.57 by November [it ruined my portfolio’s 2016 performance ]. It has been forming a base since then. In premarket it’s trading at $37.29, the highest since the November low.
I’m glad I held on. This is a very well run company at the heart of the obesity epidemic that is not going away any time soon. On the contrary, as more people join the middle class they will acquire the western disease, obesity.
PS: The cure for obesity is not insulin and drugs but healthy eating. I’ve lost over 45 pounds over the past five to seven years based on a better diet. My type 2 diabetes is gone and the blood tests are all normal. Under medical supervision almost all my heart medications have been suspended.